Liquidia and GSK restructure PRINT license; Liquidia gains rights for most inhaled uses

Liquidia Corp

New non-exclusive, royalty-free license replaces 2012 collaboration; GSK gets pre-clinical research rights only.
Liquidia may apply PRINT to all inhaled formulations except certain GSK proprietary molecules.
GSK must seek expanded license for clinical/commercial use; Liquidia retains ownership of its technology.
Agreement effective March 31, 2023; press released April 3, 2023.

item 1.01 item 1.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Liquidia Corp entered into Research License Agreement with Glaxo Group Limited (GSK) (effective 2023-03-31).

Action: entry
Agreement: license
Counterparty: Glaxo Group Limited (GSK)
Effective: 2023-03-31

Exact text from the filing

On March 31, 2023, Liquidia Corporation, a Delaware corporation (the “Company”) through Liquidia Technologies, Inc., a Delaware corporation (“Liquidia Technologies”) and wholly owned subsidiary of the Company, entered into a Research License Agreement (the “Agreement”) with Glaxo Group Limited, a company organized and existing under the laws of England (“GSK”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Liquidia Corp terminated Inhalation Collaboration and Option Agreement with Glaxo Group Limited (GSK) (effective 2023-03-31).

Action: termination
Agreement: collaboration
Counterparty: Glaxo Group Limited (GSK)
Effective: 2023-03-31

Exact text from the filing

The Agreement supersedes and replaces that certain Inhalation Collaboration and Option Agreement, dated as of June 15, 2012, by and between Liquidia Technologies and GSK, as amended on May 13, 2015, November 19, 2015 and June 24, 2019 (the “Prior Agreement”).

View on SEC.gov

Browse all material agreements →

Liquidia Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-040848

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.